Case Report

Published on 06 Feb 2024

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation

in Cancer Molecular Targets and Therapeutics

Xiaolin Ren
Kejie Li
Yang Zhang
Changlin Zou
Meng Su

Frontiers in Oncology

doi 10.3389/fonc.2024.1297156

1,300 views

Original Research

Published on 06 Feb 2024

Selective inhibition of DNA ligase IV provides additional efficacy to the treatment of anaplastic thyroid cancer

in Cancer Molecular Targets and Therapeutics

Sathya Neelature Sriramareddy
Majeed Jamakhani
Léa Vilanova
Hélène Brossel
Bernard Staumont
Malik Hamaidia

Frontiers in Oncology

doi 10.3389/fonc.2024.1323313

2,190 views

Original Research

Published on 05 Feb 2024

The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs

in Cancer Molecular Targets and Therapeutics

Weiguo Gu
Penghui Liu
Jiaming Tang
Jianfei Lai
Siya Wang
Jiaming Zhang
Jinbiao Xu
Jianxiong Deng
Feng Yu
Chao Shi

Frontiers in Oncology

doi 10.3389/fonc.2023.1288468

1,841 views
2 citations

Case Report

Published on 02 Feb 2024

Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report

in Cancer Molecular Targets and Therapeutics

Huimin Zhang
Xiaofeng Cong
Chen Chen
Ziling Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1325999

1,474 views
1 citation

Original Research

Published on 31 Jan 2024

Outcomes and complications of postoperative seroma cavities following soft-tissue sarcoma resection

in Cancer Molecular Targets and Therapeutics

Logan M. Andryk
John C. Neilson
Adam N. Wooldridge
Donald A. Hackbarth
Meena Bedi
Keith E. Baynes
John A. LoGiudice
Sonia M. Slusarczyk
David M. King

Frontiers in Oncology

doi 10.3389/fonc.2024.1250069

3,674 views

Review

Published on 30 Jan 2024

Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours

in Cancer Molecular Targets and Therapeutics

Kamilla JA. Bigos
Conrado G. Quiles
Sapna Lunj
Danielle J. Smith
Mechthild Krause
Esther GC. Troost
Catharine M. West
Peter Hoskin
Ananya Choudhury

Frontiers in Oncology

doi 10.3389/fonc.2024.1331355

5,987 views
10 citations

Original Research

Published on 24 Jan 2024

The association and clinicopathological significance of Integrin alphavbeta6 and Rac1 expression in gastric carcinoma

in Cancer Molecular Targets and Therapeutics

Junjian Yu
Wenyu Jia
Qi Liu
Antai Yuan
Zhuoyu Jia
YuQi Sun
Zequn Li
Shougen Cao

Frontiers in Oncology

doi 10.3389/fonc.2024.1347270

1,002 views
1 citation

Case Report

Published on 24 Jan 2024

Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Yajun Liang
Liya Hu
Huanlei Wu
Tiejun Yin
Jun Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1292319

1,699 views
1 citation

Original Research

Published on 24 Jan 2024

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

in Cancer Molecular Targets and Therapeutics

Yu Wang
Shunsuke Shimosaki
Emi Ikebe
Hidekatsu Iha
Jun-ichi Yamamoto
Nichole Fife
Tomonaga Ichikawa
Mitsuo Hori
Masao Ogata
Yoshiyuki Tsukamoto

Frontiers in Oncology

doi 10.3389/fonc.2023.1272528

2,363 views
1 citation

Review

Published on 22 Jan 2024

Pediatric low-grade glioma models: advances and ongoing challenges

in Cancer Molecular Targets and Therapeutics

Griselda Metta Yvone
Joshua J. Breunig

Frontiers in Oncology

doi 10.3389/fonc.2023.1346949

2,616 views
5 citations

Case Report

Published on 22 Jan 2024

Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis

in Cancer Molecular Targets and Therapeutics

Majd Al Assaad
Nara Shin
Michael Sigouros
Jyothi Manohar
Zoia Antysheva
Nikita Kotlov
Daria Kiriy
Anastasiia Nikitina
Mikhail Kleimenov
Anastasiya Tsareva

Frontiers in Oncology

doi 10.3389/fonc.2023.1274163

1,840 views
1 citation

Editorial

Published on 19 Jan 2024

Editorial: Mechanisms of drug resistance to targeted therapy in malignancies

in Cancer Molecular Targets and Therapeutics

Masatsugu Hamaji

Frontiers in Oncology

doi 10.3389/fonc.2024.1363808

615 views

Original Research

Published on 18 Jan 2024

Depletion of the m1A writer TRMT6/TRMT61A reduces proliferation and resistance against cellular stress in bladder cancer

in Cancer Molecular Targets and Therapeutics

Ida Monshaugen
Luisa Luna
Jayden Rhodes
Felicia Iselin Svensson Kristiansen
Anna Lång
Stig Ove Bøe
Anindya Dutta
Zhangli Su
Arne Klungland
Rune Ougland

Frontiers in Oncology

doi 10.3389/fonc.2023.1334112

2,362 views
1 citation

Original Research

Published on 15 Jan 2024

Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma

in Cancer Molecular Targets and Therapeutics

Khandker Mohammad Khalid
Wishrawana S. Ratnayake
Christopher A. Apostolatos
Mildred Acevedo-Duncan

Frontiers in Oncology

doi 10.3389/fonc.2023.1213715

1,661 views

Original Research

Published on 12 Jan 2024

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

in Cancer Molecular Targets and Therapeutics

Delfina Popiel
Aleksandra Stańczak
Monika Skupińska
Agata Mikołajczyk
Paulina Stańczak
Filip Mituła
Joanna Hucz-Kalitowska
Kinga Jastrzębska
Damian Smuga
Jakub Dominowski

Frontiers in Oncology

doi 10.3389/fonc.2023.1293728

2,132 views

Review

Published on 11 Jan 2024

Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity

in Cancer Molecular Targets and Therapeutics

Dennis Christoph Harrer
Florian Lüke
Tobias Pukrop
Lina Ghibelli
Christopher Gerner
Albrecht Reichle
Daniel Heudobler

Frontiers in Oncology

doi 10.3389/fonc.2023.1289222

2,638 views

Navigation group

Articles

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation

Selective inhibition of DNA ligase IV provides additional efficacy to the treatment of anaplastic thyroid cancer

The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs

Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report

Outcomes and complications of postoperative seroma cavities following soft-tissue sarcoma resection

Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours

The association and clinicopathological significance of Integrin alphavbeta6 and Rac1 expression in gastric carcinoma

Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

Pediatric low-grade glioma models: advances and ongoing challenges

Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis

Editorial: Mechanisms of drug resistance to targeted therapy in malignancies

Depletion of the m1A writer TRMT6/TRMT61A reduces proliferation and resistance against cellular stress in bladder cancer

Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity